南京 [切换城市] 南京招聘南京生物/制药/医疗器械招聘南京生物工程/生物制药招聘

Team Leader of Stem Cells Lab(职位编号:011)

南京马龙医药研发有限公司

  • 公司规模:少于50人
  • 公司性质:外资(非欧美)
  • 公司行业:制药/生物工程  学术/科研

职位信息

  • 发布日期:2013-01-15
  • 工作地点:南京-浦口区
  • 招聘人数:1
  • 工作经验:三年以上
  • 学历要求:博士
  • 语言要求:英语良好
  • 职位类别:生物工程/生物制药  医药技术研发管理人员

职位描述

工作地点: 南京,浦口
最低学历 :博士

工作性质: 全职


1. Research emphasis will be focused on biology and adult stem cell research and the development of new based stem cells therapy and medication.

2. Make SOP about adult stem cells lab storage and purification.

3. Supervise all the stem cell activities in the lab as a team leader.

Requirements:

The successful candidate will have:

1. Ph.D. degree in Biochemistry, Biotechnology or Molecular biology or Medical Doctor etc, better to have a PhD or Post PhD from Universities in the US or EU.

2. We are looking for PhD with at least 3 years experience in stem cells Lab.

3. Excellent written and oral communication skills in English

4. Experienced candidates with research background stem cells technoloty are preferred.

5. Overseas experiences, working or studying, are the plus.

公司介绍

MAPI Pharma Group is a new multi national company in Israel, Germany, HK and China, and is developing a unique and novel way of tapping the API (Active Pharmaceutical Ingredient) market for Generic Pharmaceuticals, and then develops the most effective route of production, and physical form of the API production will be done in new plants in China and Germany.

MAPI Pharma Group will be one of the leading players in the API markets. Using its excellent networking in these territories, MAPI will provide generic intermediates & API's and in parallel will develop finish dosage forms either to MAPI's API's, as a vertically integrated company and generic to other leading brands. These dosage forms might be simple or complex generics like controlled release. At the beginning, MAPI will focus on intermediates & API's forms which represent about 80% of the pharmaceutical market as well as intermediate API for pharmaceuticals.

The Company will develop more than 20 new advanced generic Intermediates and API's for which their patents will expire till 2020, and also will develop new patents, as well as at an estimated rate of 2-3 new molecules per annum.